Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.
Like everything else related to the Indiana Fever, corporate sponsorship for the WNBA team was one thing in the B.C.C. Era (Before Caitlin Clark) and something much bigger since the sharp-shooting, precise-passing guard arrived in town.
Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk’s Wegovy.
Syndeio Biosciences sees burgeoning potential to treat mental health and cognitive conditions, including Alzheimer’s and depression, with therapies that target the almost countless minuscule brain synapses that give people the ability to think and function.
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
The Purdue University Board of Trustees on Friday unanimously approved a 50-year master plan for the school’s downtown campus that proposes more than a dozen buildings across 28 acres.
The Global Entrepreneurship Congress kicked of Monday with a discussion led by Gov. Mike Braun and companies including Eli Lilly. An associated event featured a fireside chat between High Alpha Managing Partner Scott Dorsey and business author Brad Feld.
SEA 463 extends the state’s child care expenditure tax credit, which allows a business to claim a credit of up to 50% of qualified expenditures to help set up on-site or near-site child care facilities for the business’s employees.
Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.
Many companies have heeded calls from shareholders to tie CEO compensation more closely to performance. As a result, a large proportion of pay packages consist of stock awards.
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and sensory hyperexcitability disorders.
The Tobias-Lechleiter Institute will focus on getting more Hoosiers enrolled in clinical trials and advancing medical research at IU Health and the IU School of Medicine.
Last October, the WNBA Players’ Association announced it would opt out of the league’s current collective bargaining agreement two years early at the end of this season.
